Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Abstract Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.

[1]  T. Hirano,et al.  Structure and expression of human B cell stimulatory factor‐2 (BSF‐2/IL‐6) gene. , 1987, The EMBO journal.

[2]  V. Diehl,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .

[3]  Juan Hidalgo,et al.  Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain , 2014, The Journal of Neuroscience.

[4]  Jing-Pian Peng,et al.  The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization , 2006, Molecular Immunology.

[5]  C. Agrati,et al.  Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replication , 2005, Virology.

[6]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[7]  Matthias Ochs,et al.  The micromechanics of lung alveoli: structure and function of surfactant and tissue components , 2018, Histochemistry and Cell Biology.

[8]  Q. Wang,et al.  [Bioinformatics analysis on molecular mechanism of ribavirin and interferon-α in treating MERS-CoV]. , 2016, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[9]  Lucy A. Perrone,et al.  Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection1 , 2005, The Journal of Immunology.

[10]  A. Kimura,et al.  IL‐6: Regulator of Treg/Th17 balance , 2010, European journal of immunology.

[11]  J. Kolls,et al.  Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense , 2017, Mucosal Immunology.

[12]  M. Rincón,et al.  Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells1 , 2008, The Journal of Immunology.

[13]  J. Scheller,et al.  Interleukin-6 and its receptor: from bench to bedside , 2006, Medical Microbiology and Immunology.

[14]  J. Frank,et al.  Pulmonary epithelial barrier function: some new players and mechanisms. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[15]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[16]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[17]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[18]  John T. Chang,et al.  A gp130–Src–YAP module links inflammation to epithelial regeneration , 2015, Nature.

[19]  Oly Banerjee,et al.  COVID 19 could trigger global diabetes burden – A hypothesis , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[20]  Chun Zhang,et al.  Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update , 2017, Front. Immunol..

[21]  S. Rose-John,et al.  Multilevel Regulation of IL‐6R by IL‐6–sIL‐6R Fusion Protein According to the Primitiveness of Peripheral Blood‐Derived CD133+ Cells , 2006, Stem cells.

[22]  W. Shi,et al.  Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. , 2015, Cell metabolism.

[23]  T. Taniguchi,et al.  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. , 1988, Science.

[24]  J. Kolls,et al.  Targeting IL-17 and TH17 cells in chronic inflammation , 2012, Nature Reviews Drug Discovery.

[25]  A. Kumawat,et al.  Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells , 2018, Cell Communication and Signaling.

[26]  中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.  The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China./ 新型冠状病毒肺炎流行病学特征分析 , 2020 .

[27]  E. Holler,et al.  PROGNOSTIC VALUE OF INTERLEUKIN 6, PROCALCITONIN, AND C-REACTIVE PROTEIN LEVELS IN INTENSIVE CARE UNIT PATIENTS DURING FIRST INCREASE OF FEVER , 2006, Shock.

[28]  M. Rodríguez-González,et al.  New onset severe right ventricular failure associated with COVID-19 in a young infant without previous heart disease , 2020, Cardiology in the Young.

[29]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[30]  D. Furst,et al.  Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. , 2014, Seminars in arthritis and rheumatism.

[31]  D. Teachey,et al.  Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023. , 2016, Blood.

[32]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[33]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[34]  Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia , 2020, Use of Patented Traditional Chinese Medicine against COVID-19.

[35]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[36]  Simon A. Jones,et al.  Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 , 2005, The Journal of Immunology.

[37]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[38]  V. Aran,et al.  Neuromechanisms of SARS-CoV-2: A Review , 2020, Frontiers in Neuroanatomy.

[39]  J. González-Rubio,et al.  Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm , 2020, Frontiers in Immunology.

[40]  J. Teijaro.  Cytokine storms in infectious diseases , 2017, Seminars in Immunopathology.

[41]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[42]  P. Liu,et al.  Gross examination report of a COVID-19 death autopsy. , 2020, Fa yi xue za zhi.

[43]  J. Weissenbach,et al.  Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Lucy A. Perrone,et al.  Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection1 , 2005, Journal of Immunology.

[45]  J. Buckner,et al.  IL-6: a cytokine at the crossroads of autoimmunity. , 2018, Current opinion in immunology.

[46]  F. Swirski,et al.  Cytokine storm and sepsis disease pathogenesis , 2017, Seminars in Immunopathology.

[47]  M. Akiyama,et al.  JAK–STAT and JAK–PI3K–mTORC1 Pathways Regulate Telomerase Transcriptionally and Posttranslationally in ATL Cells , 2012, Molecular Cancer Therapeutics.

[48]  J. Scheller,et al.  Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. , 2014, Seminars in immunology.

[49]  P. Muntner,et al.  Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients , 2019, Arthritis care & research.

[50]  Stefan Rose-John,et al.  IL-6 pathway in the liver: From physiopathology to therapy. , 2016, Journal of hepatology.

[51]  R. Pazdur,et al.  FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome , 2018, The oncologist.

[52]  Dr Irin Hossain, MPH,et al.  The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) In Bangladesh: A Descriptive Study , 2020, Journal of Medical Science And clinical Research.

[53]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[54]  M. Hallek,et al.  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. , 2013, The Journal of clinical investigation.

[55]  James R. Rogers,et al.  Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study , 2017, Arthritis & rheumatology.

[56]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[57]  Yu Huang,et al.  IL‐6 in diabetes and cardiovascular complications , 2014, British journal of pharmacology.

[58]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.

[59]  Pınar Pir,et al.  Integration of transcriptomic profile of SARS-CoV-2 infected normal human bronchial epithelial cells with metabolic and protein-protein interaction networks , 2020, Turkish journal of biology = Turk biyoloji dergisi.

[60]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[61]  S. Gabriel,et al.  Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial , 2019, Arthritis & rheumatology.

[62]  P. Woo,et al.  Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[63]  Simon A. Jones,et al.  Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer , 2018, Nature Reviews Immunology.

[64]  Yuka Kanno,et al.  Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.

[65]  J. Scheller,et al.  The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling , 2018, The Journal of Biological Chemistry.

[66]  Novel Coronavirus Pneumonia Emergency Response Epidemiol Team.  [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.